New prospects for PCSK9 inhibition

European Society of Cardiology/European Atherosclerosis Society Task Force, Ulf Landmesser (Lead / Corresponding author), M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J. F. Belch, Jan Borén, Michel Farnier, Brian A. Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Luscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis ZamoranoFausto Pinto, Lale Tokgozoglu, Jeroen J. Bax, Alberico L. Catapano

Research output: Contribution to journalComment/debatepeer-review

11 Citations (Scopus)


This commentary refers to ‘2017 update of ESC/EAS task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia’, by U Landmesser et al., doi: 10.1093/eurheartj/ehx549.
Original languageEnglish
Pages (from-to)2600-2601
Number of pages2
JournalEuropean Heart Journal
Issue number27
Early online date22 Mar 2018
Publication statusPublished - 14 Jul 2018


Dive into the research topics of 'New prospects for PCSK9 inhibition'. Together they form a unique fingerprint.

Cite this